MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms MONARCC
- 04 Jul 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 New trial record